OS THERAPIES INCORPORATED Financing Cash Flow
OS THERAPIES INCORPORATED (OSTX) reported Financing Cash Flow of $10.03 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-14
- OS THERAPIES INCORPORATED net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $4.82M, a 94.05% increase year-over-year.
- OS THERAPIES INCORPORATED net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $5.21M, a 394.90% increase year-over-year.
- OS THERAPIES INCORPORATED net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $2.12M, a 64.90% decline year-over-year.
- OS THERAPIES INCORPORATED net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $3.78M, a 26.56% decline year-over-year.
- OS THERAPIES INCORPORATED net cash provided by (used in) financing activities for fiscal 2025 was $9.44M, a 26.11% decline from fiscal 2024.
- OS THERAPIES INCORPORATED net cash provided by (used in) financing activities for fiscal 2024 was $12.78M, a 344.67% increase from fiscal 2023.
- OS THERAPIES INCORPORATED net cash provided by (used in) financing activities for fiscal 2023 was $2.87M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $10.03M 10-Q · filed 2026-08-14 | $12.16M derived: sum of 3 quarters · filed 2026-08-14 | $15.94M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $5.21M 10-Q · filed 2026-05-18 | $7.33M derived: sum of 2 quarters · filed 2026-05-18 | $11.12M derived: sum of 3 quarters · filed 2026-05-18 | $13.60M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $2.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $5.90M derived: sum of 2 quarters · filed 2026-03-31 | $8.39M derived: sum of 3 quarters · filed 2026-08-14 | $9.44M 10-K · filed 2026-03-31 |
| 2025-09-30 | $3.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $6.26M derived: sum of 2 quarters · filed 2026-08-14 | $7.32M 10-Q · filed 2025-11-14 | $13.37M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $2.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $3.54M 10-Q · filed 2026-08-14 | $9.59M derived: sum of 3 quarters · filed 2026-08-14 | $14.74M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $1.05M 10-Q · filed 2026-05-18 | $7.10M derived: sum of 2 quarters · filed 2026-05-18 | $12.25M derived: sum of 3 quarters · filed 2026-05-18 | $13.13M derived: sum of 4 quarters · filed 2026-05-18 |
| 2024-12-31 | $6.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $11.20M derived: sum of 2 quarters · filed 2026-03-31 | $12.07M derived: sum of 3 quarters · filed 2026-03-31 | $12.78M 10-K · filed 2026-03-31 |
| 2024-09-30 | $5.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $6.02M derived: sum of 2 quarters · filed 2025-11-14 | $6.73M 10-Q · filed 2025-11-14 | $7.62M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $875.88K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | $1.58M 10-Q · filed 2025-08-18 | $2.47M derived: sum of 3 quarters · filed 2025-08-18 | $3.32M derived: sum of 4 quarters · filed 2025-08-18 |
| 2024-03-31 | $702.98K 10-Q · filed 2025-05-15 | $1.60M derived: sum of 2 quarters · filed 2025-05-15 | $2.44M derived: sum of 3 quarters · filed 2025-05-15 | $2.97M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $894.06K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.74M derived: sum of 2 quarters · filed 2025-03-31 | $2.26M derived: sum of 3 quarters · filed 2025-03-31 | $2.87M 10-K · filed 2025-03-31 |
| 2023-09-30 | $843.41K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-15 | $1.37M derived: sum of 2 quarters · filed 2024-11-15 | $1.98M 10-Q · filed 2024-11-15 | |
| 2023-06-30 | $525.08K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $1.14M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $610.77K 10-Q · filed 2024-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |